Cardiovascular
 
Dermatology
 
Endocrinology
 
Internal medicine
 
Medicine (General)
 
Head and neck
 
Immunology
 
Neurology
 
Oncology
 
Bone health
 
Pediatrics
 
Mental health
 
Respiratory medicine
 
Surgery
 
Veterinary medicine
 
Regional news
 
Most popular
 
Archive News

medwireNews Interviews
 
Friendly Links


Follow me on Twitter
Docosahexaenoic acid levels reduced in bipolar disorder patients
By Mark Cowen, Senior medwireNews Reporter
04 December 2012
J Psychiatr Res 2013; Advance online publication

medwireNews: Results from an Italian study show that plasma levels of docosahexaenoic acid (DHA) are significantly lower in patients with bipolar disorder than in mentally healthy individuals.

However, plasma levels of other fatty acids appear to be increased in bipolar disorder patients.

Writing in the Journal of Psychiatric Research, Massimiliano Pomponi (Catholic University of the Sacred Heart, Rome) and team say that "DHA may provide a basis for possible pharmacological intervention in psychiatric disorders."

The researchers used gas chromatography/mass spectrometry to analyze fasting blood samples collected from 42 patients with bipolar disorder and 57 age- and gender-matched mentally healthy individuals (controls) for levels of 15 fatty acids.

All of the participants had a typical Mediterranean-style diet that is high in levels of root vegetables, green vegetables, fruit, fish, poultry, and olive oil, the team notes.

The team found that median DHA levels were a significant 53.7% lower in bipolar disorder patients than controls, at 47.7 versus 102.9 µmol/L.

The difference in DHA levels between the two groups remained significant after accounting for age, gender, and smoking.

Conversely, plasma levels of other fatty acids were significantly increased in bipolar disorder patients compared with controls. For example, arachidonic acid levels were increased by 35.3%, at 928.8 versus 686.6 µmol/L, alpha-linolenic acid (ALA) levels by 300.0%, at 220.7 versus 55.2 µmol/L, and eicosapentaenoic acid (EPA) levels by 89.3%, at 82.8 versus 43.7 µmol/L, in bipolar disorder patients compared with controls, respectively.

Pomponi and team write: "Our data strongly suggest that plasma DHA levels are frequently depleted in patients with bipolar disorder, although it is still unclear whether this alteration contributes to the psychiatric disorder. Indeed, it might also be a consequence of the disease and/or its pharmacological treatment (via inhibition of peroxisomal transport and/or peroxisomal oxidation)."

They conclude: "The role of DHA, as adjuvant, might be considered of possible use."

medwireNews (www.medwire-news.md) is an independent clinical news service provided by Springer Healthcare Limited. © Springer Healthcare Ltd; 2012

Free abstract

Comments
This article currently has no comments
Post a Comment

Please note, email address is required but not shown. Comments are moderated and will not appear until they have been approved. Please see the disclaimer for more information